Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 in Advanced HER2+ Cancers
NCT02512237Phase 1Terminated
- Sponsor
- Zhejiang Medicine Co., Ltd.
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 1, open-label trial of anvatabart opadotin in breast cancer and gastric cancer (GC) (4 arms), sponsored by Zhejiang Medicine Co., Ltd. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Mar 2016; status: terminated.
02
Drugs
anvatabart opadotin
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT02512237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02512237.